[go: up one dir, main page]

GB1003748A - Diagnostic compositions for the determination of blood coagulant factor levels - Google Patents

Diagnostic compositions for the determination of blood coagulant factor levels

Info

Publication number
GB1003748A
GB1003748A GB4282062A GB4282062A GB1003748A GB 1003748 A GB1003748 A GB 1003748A GB 4282062 A GB4282062 A GB 4282062A GB 4282062 A GB4282062 A GB 4282062A GB 1003748 A GB1003748 A GB 1003748A
Authority
GB
United Kingdom
Prior art keywords
bovine plasma
composition
calcium
determination
fibrinogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB4282062A
Inventor
Jane Grant Lenahan
Monroe Lloyd Miller
Raphael Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Pharmaceutical Co filed Critical Warner Lambert Pharmaceutical Co
Priority to GB4282062A priority Critical patent/GB1003748A/en
Publication of GB1003748A publication Critical patent/GB1003748A/en
Expired legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745Assays involving non-enzymic blood coagulation factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A lyophilized diagnostic composition for use in determining blood coagulaton factors consists essentially of tissue thromboplastin having a clotting time of about 30 seconds, calcium ion, bovine plasma containing stabilizing concentrations of Factor V and fibrinogen, said composition being characterized by freedom from cephalia and having a pH range of 7,2-7,6. In one example, barium sulphate adsorbed oxolated bovine plasma is added to distilled water containing sodium chloride, calcium chloride and acetone treated horse brain tissue, buffered at pH 7,2-7,6. Specification 917,012 is referred to.ALSO:A lyophilized diagnostic composition for use in determining blood coagulation factors consists essentially of tissue thromboplastin having a clotting time of about 30 seconds, calcium in, bovine plasma containing stabilizing concentrations of Factor V and fibrinogen, said composition being characterised by freedom from cephalin and having a pH range of 7.2 to 7.6. In one example, barium-sulphate-adsorbed oxalated bovine plasma is added to distilled water containing sodium chloride, calcium chloride and acetone-treated horse brain tissue, buffered at 7.2 to 7.6. Specification 917,012 is referred to.
GB4282062A 1962-11-13 1962-11-13 Diagnostic compositions for the determination of blood coagulant factor levels Expired GB1003748A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB4282062A GB1003748A (en) 1962-11-13 1962-11-13 Diagnostic compositions for the determination of blood coagulant factor levels

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB4282062A GB1003748A (en) 1962-11-13 1962-11-13 Diagnostic compositions for the determination of blood coagulant factor levels

Publications (1)

Publication Number Publication Date
GB1003748A true GB1003748A (en) 1965-09-08

Family

ID=10426116

Family Applications (1)

Application Number Title Priority Date Filing Date
GB4282062A Expired GB1003748A (en) 1962-11-13 1962-11-13 Diagnostic compositions for the determination of blood coagulant factor levels

Country Status (1)

Country Link
GB (1) GB1003748A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11604026B2 (en) 2019-03-14 2023-03-14 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
US11634257B2 (en) 2017-10-09 2023-04-25 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11634257B2 (en) 2017-10-09 2023-04-25 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
US11604026B2 (en) 2019-03-14 2023-03-14 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
US11609042B2 (en) 2019-03-14 2023-03-21 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use
US11609043B2 (en) 2019-03-14 2023-03-21 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use
US11740019B2 (en) 2019-03-14 2023-08-29 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
US11747082B2 (en) 2019-03-14 2023-09-05 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use
US11815311B2 (en) 2019-03-14 2023-11-14 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use
US11994343B2 (en) 2019-03-14 2024-05-28 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use

Similar Documents

Publication Publication Date Title
GB917012A (en) Reagent for the control of coagulability of blood
Ratnoff et al. The activation of Christmas factor (factor IX) by activated plasma thromboplastin antecedent (activated factor XI)
Godal et al. Gelation of soluble fibrin in plasma by ethanol
DE3587941D1 (en) DEVICE FOR PROVISIONAL REPERFUSION TREATMENT OF HEART ATTACK SYMPTOMS.
ES2035920T3 (en) AEROLIZATION OF THERAPEUTIC PROTEIN AGENT.
ES524992A0 (en) PROCEDURE TO HYGIENIZE OR PASTEIZE HUMAN FRIBRINOGEN
GB229644A (en) A method of producing a substance adapted to tampon wounds
ATE13304T1 (en) METHODS FOR PURIFICATION OF BLOOD COAGULATION FACTORS II, VII, IX AND/OR X AND PREPARATIONS MADE THEREFORE.
ES2037664T3 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMORRHAGIC DISORDERS.
ES2042532T3 (en) PROCEDURE FOR PREPARING AN AGENT INTENDED FOR THERAPY OR PROPHYLAXIS OF HEMOSTATIC DISORDERS.
ES535409A0 (en) PROCEDURE TO PASTEIZE A RADICAL-HUMAN PLASMA
GB1003748A (en) Diagnostic compositions for the determination of blood coagulant factor levels
Girolami et al. Crossover electrophoresis (electrosyneresis) visualization of the abnormal factor X (factor X Friuli)
SE336198B (en)
McClaughry et al. Nature of an accelerator of prothrombin activation arising during storage of purified prothrombin.
GB1013192A (en) Diagnostic reagent composition for use in determining blood coagulation factors
US4391746A (en) Blood-coagulation-promoting products and methods of preparing them
Mellanby et al. Calcium and blood coagulation
DE3775278D1 (en) TOPICAL METHOTREXATE PREPARATION FOR TREATING HYPERPROLIFERATIVE EPITHELIC DISEASES.
Rothstein et al. Ferritin and antiferritin serum treatment of dogs in irreversible hemorrhagic shock
ATE136122T1 (en) METHOD FOR DETERMINING FIBRIN
Maltaner Enhancing effect of Mg++ on clotting activity of Ca++
GB727631A (en) Absorbent articles intended for surgical, dental and sanitary purposes
ATE42087T1 (en) PROCESS FOR THE PREPARATION OF DENSITY ANHYDROUS SODIUM CARBONATE AND DENSITY ANHYDROUS SODIUM CARBONATE PRODUCED BY THIS PROCESS.
Ganrot et al. Prothrombin derivatives in human serum. Isolation and some properties of the non-thrombin fragments